CytomX Therapeutics Reaches Analyst Target Price
May 02, 2024 at 07:14 AM EDT
In recent trading, shares of CytomX Therapeutics Inc (CTMX) have crossed above the average analyst 12-month target price of $2.75, changing hands for $5.13/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..